Management of Recurrent Depression in Primary Care
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The patient is a 37-year-old woman with a major depressive episode of recent onset. She had 2 previous episodes 1 and 3 years earlier, which had been treated by her primary care physician with fluoxetine for 6 months each time. There is no evidence of bipolar illness. She wants to know which treatment is right for her at this point.Major depressive disorder is a highly prevalent condition in the general population. Its chronic and recurrent nature is getting increasing attention [1]. Approximately 8 of 10 people experiencing a major depressive disorder will have 1 or more episodes during their lifetime, i.e., a recurrent major depressive disorder [2]. In some patients, the episodes are separated by many symptom-free years of normal functioning. For others, the episodes become increasingly frequent [3]. This latter course appears to be the more prevalent, both in psychiatric and primary care settings [4, 5, 6, 7, 8, 9].Partial remission between episodes, not full recovery, appears to be the rule and is associated with residual disability [7]. At least 1 patient out of 3 is likely to relapse within a year [4, 5, 6]. Two major risk factors associated with relapse appear to be persistence of subthreshold or subclinical symptoms and number of episodes of major depression [4, 5, 6, 7]. As a result, for most people, depression is a life-long episodic disorder with multiple recurrences (averaging 1 episode in every 5-year period) [8].The adverse economic, interpersonal and medical consequences (e.g. work impairment, and family dysfunction) of the course of unipolar depression are considerable [1]. The case vignette thus highlights a common clinical problem faced by clinicians, whether in primary care or specialty settings. As our patient meets the criteria for recurrent depression developed by Frank et al. [10](≥3 episodes of unipolar depression, with the immediately preceding episode being no more than 2.5 years before the onset of the present episode), there is an 80–90% chance of relapse within 2 years from remission of depression and discontinuation of antidepressant treatment [10, 11].Since the chances of relapse are so high, the primary care physician would think of referral to a psychiatric specialist as the next logical step, relying on his/her clinical judgment for further therapeutic strategies. There is very little empirical support, however, that this choice, per se, entails substantial benefits for the patient. An impressive series of studies point to this conclusion.Simon et al. [12]compared the 6-month outcome in depressed patients receiving antidepressant prescriptions either from psychiatrists or primary care physicians. The proportion receiving antidepressant medication at an adequate dose for 90 days or more was similar in both cases (about 50%). The two groups showed similar rates of improvement in all measures of symptom severity and functioning [12]. Even collaboration between primary care physicians and mental health consultants [13]or implementation of clinical-practice guidelines and practice-based education [14]did not yield any significant advantage over usual care in long-term outcome.Three hundred eighty-six patients with recurrent major depression or dysthymia who had recovered after 8 weeks of antidepressant treatment by their primary care physicians were randomized to a relapse prevention program (involving a depression specialist) or usual primary care [15]. There were no significant differences in the relapse rate over a 12-month follow-up period.What emerges from these studies is the failure of the mental health specialist to improve the outcome of major depression in the primary care setting [16]. The introduction of more tolerable and easy-to-use antidepressant drugs, compared with the traditional tricyclics (which required dosages that nonpsychiatric physicians were reluctant to use), has blurred the difference among physicians in prescribing antidepressant drugs. At the same time, an impressive amount of pharmaceutical propaganda has clouded the evidence which underlies clinical decisions [17]. The main therapeutic strategies are now described, taking into consideration the most reliable findings available.Maintenance pharmacotherapy has been advocated as an effective tool for reducing relapses and recurrences in major depression [18, 19, 20]. A number of studies have demonstrated the superiority of antidepressant drugs (mostly tricyclics) against placebo in protecting the patient from relapsing [18, 19, 20]. Their average duration was 17 months [21]and only one small trial of imipramine reached 5 years [22]. Viguera et al. [23]analyzed 27 studies with variable length of antidepressant treatment which reported follow-up on drug discontinuation. Duration of drug treatment did not seem to affect long-term prognosis once the drug was discontinued. In clinical terms, this means that it does not matter whether you have treated a depressed patient for 3 months or 3 years, when you s
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“diabetologists, as other medical specialists, emphasize the importance of nonpharmacological strategies [”
BackgroundPsychological well-being: Meaning, measurement, and implications for psychotherapy research
Ryff, C. D., & Singer, B. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000289026 · Cited by 1,295
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Prevention of Recurrent Depression With Cognitive Behavioral Therapy: Preliminary Findings
Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., & Belluardo, P. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.816 · Cited by 491
Self-citationThompson, C., Kinmonth, A., Stevens, L., Pevele, R., Stevens, A., Ostler, K., Pickering, R., Baker, N., Henson, A., Preece, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(99)03171-2 · Cited by 489
The Clinical Course of Unipolar Major Depressive Disorders
Judd, L. L. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230015002 · Cited by 460
Six-Year Outcome for Cognitive Behavioral Treatment of Residual Symptoms in Major Depression
Fava, G. A., Rafanelli, C., Grandi, S., Canestrari, R., & Morphy, M. A. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1443 · Cited by 299
Self-citationSubclinical symptoms in mood disorders: pathophysiological and therapeutic implications
FAVA, G. A. (1999) · Psychological Medicine · doi:10.1017/s0033291798007429 · Cited by 258
Self-citationRemission and relapse in major depression: a two-year prospective follow-up study
Ramana, R., Paykel, E. S., Cooper, Z., Hayhurst, H., Saxty, M., & Surtees, P. G. (1995) · Psychological Medicine · doi:10.1017/s0033291700033134 · Cited by 236
Ormel, J. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820220009001 · Cited by 216
Relapse of depression in primary care: Rate and clinical predictors
Lin, E. H. B. (1998) · Archives of Family Medicine · doi:10.1001/archfami.7.5.443 · Cited by 152
Residual symptoms in depression
Fava, G. A., Fabbri, S., & Sonino, N. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00226-9 · Cited by 137
Self-citationFava, G. A., Ruini, C., Rafanelli, C., & Grandi, S. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.12.2094 · Cited by 88
Self-citationTreatment Approaches to Major Depressive Disorder Relapse
Schmidt, M. E., Fava, M., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063643 · Cited by 60
Treatment Approaches to Major Depressive Disorder Relapse
Fava, M., Schmidt, M. E., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063644 · Cited by 44
Tolerance in antidepressant treatment
Baldessarini, R. J., Ghaemi, S. N., & Viguera, A. C. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063641 · Cited by 42 · cited 1×
“Even though lifelong pharmacotherapy is chosen (table 2 ), there is the common and vexing problem of relapse during pharmacotherapy [”
BackgroundSonino, N., & Fava, G. A. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00252-x · Cited by 11
Self-citation
Cited by
Six-Year Outcome of Cognitive Behavior Therapy for Prevention of Recurrent Depression
Fava, G. A., Ruini, C., Rafanelli, C., Finos, L., Conti, S., & Grandi, S. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1872 · Cited by 392
Self-citationWell-Being Therapy of Generalized Anxiety Disorder
Fava, G. A., Ruini, C., Rafanelli, C., Finos, L., Salmaso, L., Mangelli, L., & Sirigatti, S. (2005) · Psychotherapy and Psychosomatics · doi:10.1159/000082023 · Cited by 344
Self-citationHollon, S. D., Jarrett, R. B., Nierenberg, A. A., Thase, M. E., Trivedi, M., & Rush, A. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0408 · Cited by 259
van der Feltz-Cornelis, C. M., van Oppen, P., Adèr, H. J., & van Dyck, R. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000093949 · Cited by 138
The Intellectual Crisis of Psychiatric Research
Fava, G. A. (2006) · Psychotherapy and Psychosomatics · doi:10.1159/000092890 · Cited by 79
“Accordingly, the diagnostic criteria for a major depressive disorder identify a syndrome that may be responsive to antidepressant drugs [”
BackgroundSelf-citation
Metadata
- Authors
- Fava, G. A., Ruini, C., & Sonino, N.
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2002-12-16
- Volume
- 72
- Issue
- 1
- Pages
- 3-9
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2054436263
- Cited by
- 20
- References
- 17
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.